Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, announced new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024.
“We are thankful for the opportunity provided by ASTRO to share the latest findings, which emphasize the pivotal role of NavDx in influencing clinical management”
NavDx is the first and only clinically validated circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test that aids in the detection of HPV-driven cancer. The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease. Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications.
Recommended: Top 5 Application Security Trends for CIOs in Finance and Banking
“We are thankful for the opportunity provided by ASTRO to share the latest findings, which emphasize the pivotal role of NavDx in influencing clinical management,” commented Barry M. Berger, M.D., Chief Medical Officer at Naveris. “The data being showcased highlight the critical role circulating tumor HPV DNA assessment can play in shaping patient care strategies. We are enthusiastic about the progress made through our extensive collaborations with a diverse array of partners in the oncology community,” he concluded.
These presentations showcase the utility of NavDx in the management of HPV-driven head and neck cancer at every stage of disease, from treatment response and guidance to surveillance and detection of recurrence:
Recommended: Cybersecurity: What’s on the Horizon for 2024?
[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]
